https://www.selleckchem.com/products/LBH-589.html
928; 95% CI, 0.881-0.977; P = 0.004)]. Subgroup analysis indicated that the survival benefit of adjuvant chemoradiotherapy was more significant in patients with female (HR, 0.860; 95% CI, 0.798-0.926; P = 0.005 for interaction) or T3 (HR, 0.905; 95% CI, 0.855-0.957; P = 0.04 for interaction) or lymph nodes positive (HR, 0.883; 95% CI, 0.832-0.938; P = 0.005 for interaction). Adjuvant CRT was associated with improved survival compared with adjuvant CT in patients with resection of pancreatic ductal adenocarcinoma. The benefit was more si
Like
Comment
Share
